For generations, the shadow of valproate has fallen most heavily on women of childbearing age, but a quieter question has lingered: what of the fathers? A sweeping Taiwanese study spanning 2.5 million births and fifteen years now offers a measured answer — that a father's use of this common antiseizure drug before conception does not appear to raise the risk of autism, ADHD, or birth defects in his children. The finding does not close the conversation, but it does push back against recent warnings from the United Kingdom, reminding us that medical caution, however well-intentioned, must be con
Paternal valproate use shows no link to autism, ADHD in offspring
People with epilepsy need long-term treatment during their reproductive years
Mark
Why does it matter whether fathers take this drug? Isn't the concern really about what happens in pregnancy?
Mimi
Yes, but men with epilepsy need to keep taking their medication to stay healthy. If they're told the drug might harm their future children, they face a real dilemma—stop a medication that controls their seizures, or avoid having kids. This study suggests that dilemma might not be necessary.
Mark
So the UK warning was based on what, exactly?
Mimi
European studies that raised concerns about paternal use. But those studies were smaller or looked at different populations. This Taiwan research is much larger and found nothing—which doesn't mean the UK was wrong, just that the picture is more complicated than anyone realized.
Mark
What's the catch? There's always a catch.
Mimi
The follow-up period. Some kids were only tracked for five years. Autism and ADHD can show up later, so a longer observation might tell a different story. That's why the researchers are careful not to say the drug is definitely safe—just that they found no evidence of harm in this particular dataset.
Mark
If this is true, why hasn't anyone studied it before?
Mimi
They have, but not at this scale. Maternal effects were the priority because pregnancy is when the drug actually crosses into the developing fetus. Paternal exposure is indirect—the drug is in the father's body, not the baby's. It took a massive database and years of follow-up to generate enough data to see whether any signal existed.
Mark
What happens now?
Mimi
Doctors probably won't change their prescribing practices immediately. The researchers are saying we need more evidence from other countries and longer studies. But for men with epilepsy who want to have children, this is at least reassuring—it suggests they might not have to choose between their health and their family.
El Pulso
- Men with epilepsy have faced growing uncertainty about whether their medication could silently harm their future children — a fear amplified by UK advisories warning against valproate use in men under 55.
- The stakes are high: valproate is one of the most effective seizure-control drugs available, and restricting it without solid evidence could leave patients undertreated during their most reproductively active years.
- Taiwanese researchers combed through 2.5 million births over 15 years, isolating 1,701 children whose fathers used valproate in the critical three months before conception and tracking them for an average of 12 years.
- Initial raw differences in autism and ADHD rates vanished entirely once researchers adjusted for confounding factors, and a sibling comparison study — nature's own control group — confirmed the null finding.
- The science is not settled: some children were followed for as few as five years, and researchers are calling for longer studies across more diverse populations before any prescribing guidelines are revised.
For generations, the shadow of valproate has fallen most heavily on women of childbearing age, but a quieter question has lingered: what of the fathers? A sweeping Taiwanese study spanning 2.5 million births and fifteen years now offers a measured answer — that a father's use of this common antiseizure drug before conception does not appear to raise the risk of autism, ADHD, or birth defects in his children. The finding does not close the conversation, but it does push back against recent warnings from the United Kingdom, reminding us that medical caution, however well-intentioned, must be continually tested against evidence drawn from the full breadth of human experience.
A major Taiwanese study published in Neurology has found no evidence that fathers who take valproate — a widely used antiseizure medication — before conception increase their children's risk of autism, ADHD, intellectual disability, tic disorders, or birth defects. The research drew on 15 years of national health data covering more than 2.5 million births, following children for an average of 12 years.
Valproate's dangers during pregnancy are well established: when taken by expectant mothers, it carries serious risks of birth defects and developmental harm. That has led to strong restrictions on its use in women who might become pregnant. But the question of paternal use has remained largely unexplored — a significant gap, given that many people with epilepsy are men who require continuous treatment throughout their reproductive years.
Researchers focused on 1,701 children whose fathers had used valproate during the three months before conception, the window in which sperm develops. While raw rates of autism and ADHD were slightly elevated in this group compared to the general population, those differences disappeared entirely after accounting for factors such as the child's sex, birth weight, and parental health history. A separate analysis of 548 sibling pairs — where one child was exposed to paternal valproate and the other was not — produced the same null result.
The findings sit in direct tension with recent UK guidance advising against valproate use in men aged 55 and younger. Lead researcher Shi-Heng Wang of Taiwan's National Health Research Institutes acknowledged the contrast, noting that while the Taiwan data adds meaningful weight to the global evidence base, it should not by itself prompt changes to prescribing practices. Limitations remain: some children were tracked for as little as five years, potentially too short to capture later-emerging diagnoses. Researchers are calling for longer follow-up studies across diverse populations before any firm clinical conclusions are drawn.
A large study of births in Taiwan has found no evidence that fathers taking the antiseizure drug valproate before conception increases the risk of autism, ADHD, or birth defects in their children. The research, published August 19, 2026, in Neurology, examined more than 2.5 million births over a 15-year period and followed children for an average of 12 years to track whether they developed neurodevelopmental disorders.
Valproate is a widely used medication for controlling seizures, and it has long been known to pose serious risks when taken by pregnant women—causing birth defects and developmental problems in exposed children. Because of this danger, the drug is not recommended for women who might become pregnant. But far less has been known about whether the drug poses any risk when fathers use it. The question matters because people with epilepsy often need continuous treatment throughout their reproductive years, and many are men who want to have children.
The Taiwan study identified 1,701 children whose fathers had taken valproate during the three months before conception, the critical window when sperm develops. Researchers compared the rates of neurodevelopmental disorders and birth defects in these children against the broader population. Among all children in the study, 1.6% were diagnosed with autism and 7.7% with ADHD. Among children whose fathers took valproate, the rates were slightly higher—1.9% for autism and 10.2% for ADHD—but when researchers accounted for other factors like the child's sex, birth weight, parental age, and maternal health history, the difference disappeared. The same held true for tic disorders, intellectual disability, and birth defects. The researchers also examined 548 sibling pairs where one child was exposed to paternal valproate and the other was not, and again found no association.
The findings stand in contrast to recent warnings issued in the United Kingdom, which advised against valproate use in men 55 and younger based on concerns about offspring outcomes. Shi-Heng Wang, the study's lead author from Taiwan's National Health Research Institutes, noted that while maternal valproate use has been extensively studied and shown to carry real risks, the evidence on paternal use has been limited. "Our results show no association with use by fathers," Wang said, while acknowledging that more research is needed before changing prescribing guidelines.
The study does have limitations. Some children were followed for as little as five years, which may not have been long enough to capture all neurodevelopmental diagnoses that emerge later in childhood. Researchers also examined other commonly prescribed antiseizure medications and found no associations with adverse outcomes in offspring. Wang emphasized that the Taiwan data, drawn from a population of 2.5 million births, adds important evidence to an international conversation, but that conclusions about changing prescribing practices should wait for additional studies, particularly from other populations and with longer follow-up periods. The work was funded by Taiwan's National Science and Technology Council, Chang Gung Memorial Hospital, and the Ministry of Education.
Citas Notables
While such drugs have been extensively studied in mothers, less is known about use of these drugs by fathers.— Shi-Heng Wang, lead researcher, National Health Research Institutes, Taiwan
Our study of 2.5 million births in Taiwan adds to the evidence. It found no increased risk of disorders or malformations among children of fathers prescribed valproate or other antiseizure medications.— Shi-Heng Wang
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine